RUNX1 (RUNX family transcription factor 1), a target of microRNA miR-128-3p, promotes temozolomide resistance in glioblastoma multiform by upregulating multidrug resistance-associated protein 1 (MRP1)

References

• Abedalthagafi M, Barakeh D, Foshay K. Immunogenetics of glioblastoma: the future of personalized patient management. NPJ Precis Oncol. 2018;2:27.
   PubMed Web of Science ®Google Scholar
• Wang L, Karpova A, Gritsenko M, et al. Proteogenomic and metabolomic characterization of human glioblastoma. Cancer Cell. 2021;39(4):509–528.e520.
   PubMed Web of Science ®Google Scholar
• Macdonald D, Cascino T, Schold S, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277–1280.
   PubMed Web of Science ®Google Scholar
• Johannessen TC, Bjerkvig R. Molecular mechanisms of temozolomide resistance in glioblastoma multiforme. Expert Rev Anticancer Ther. 2012;12(5):635–642.
   PubMed Web of Science ®Google Scholar
• Zhao C, Guo R, Guan F, et al. Yang B MicroRNA-128-3p enhances the chemosensitivity of temozolomide in glioblastoma by targeting c-Met and EMT. Sci Rep.
   Google Scholar
• Yu F, Li G, Gao J, et al. SPOCK1 is upregulated in recurrent glioblastoma and contributes to metastasis and Temozolomide resistance. Cell Prolif. 2016;49(2):195–206.
   PubMed Web of Science ®Google Scholar
• Osuka S, Van Meir E. Overcoming therapeutic resistance in glioblastoma: the way forward. J Clin Invest. 2017;127(2):415–426.
   PubMed Web of Science ®Google Scholar
• Birzu C, French P, Caccese M, et al. Recurrent glioblastoma: from molecular landscape to new treatment perspectives. Cancers (Basel). 2020;13:1.
   PubMed Web of Science ®Google Scholar
• Ostrom Q, Patil N, Cioffi G, et al. Corrigendum to: CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017. Neuro Oncol. 2020. DOI:10.1093/neuonc/noaa269
   Web of Science ®Google Scholar
• Hong D, Fritz A, Finstad K, et al. Suppression of breast cancer stem cells and tumor growth by the RUNX1 transcription factor. Mol Cancer Res. 2018;16(12):1952–1964.
   PubMed Web of Science ®Google Scholar
• Levanon D, Groner Y. Structure and regulated expression of mammalian RUNX genes. Oncogene. 2004;23(24):4211–4219.
   PubMed Web of Science ®Google Scholar
• Sumazin P, Yang X, Chiu H, et al. An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell. 2011;147(2):370–381.
   PubMed Web of Science ®Google Scholar
• Teng H, Wang P, Xue Y, et al. Role of HCP5-miR-139-RUNX1 feedback loop in regulating malignant behavior of glioma cells. Mol Ther. 2016;24(10):1806–1822.
   PubMed Web of Science ®Google Scholar
• Zhao K, Cui X, Wang Q, et al. Shang R RUNX1 contributes to the mesenchymal subtype of glioblastoma in a TGFβ pathway-dependent manner. Cell Death Dis.
   Google Scholar
• Li W, Ma Q, Liu Q, et al. Circ-VPS18 knockdown enhances TMZ sensitivity and inhibits glioma progression by MiR-370/RUNX1 axis. J Mol Neurosci. 2020. DOI:10.1007/s12031-020-01749-8
   Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004. DOI:10.1016/S0092-8674(04)00045-5
   Web of Science ®Google Scholar
• Han J, LaVigne C, Jones B, et al. A ubiquitin ligase mediates target-directed microRNA decay independently of tailing and trimming. Science (New York, NY). 2020;370(6523). DOI: 10.1126/science.abc9546.
   Google Scholar
• Goodall G, Wickramasinghe V. RNA in cancer. Nat Rev Cancer. 2021;21(1):22–36.
   PubMed Web of Science ®Google Scholar
• Tumilson C, Lea R, Alder J, et al. Circulating microRNA biomarkers for glioma and predicting response to therapy. Mol Neurobiol. 2014;50(2):545–558.
   PubMed Web of Science ®Google Scholar
• Sun Y, Chen G, He J, et al. Clinical significance and potential molecular mechanism of miRNA-222-3p in metastatic prostate cancer. Bioengineered. 2021;12(1):325–340.
   PubMed Web of Science ®Google Scholar
• Lu J, Liang J, Xu M, et al. Identification of an eleven-miRNA signature to predict the prognosis of endometrial cancer. Bioengineered. 2021;12(1):4201–4216.
   PubMed Web of Science ®Google Scholar
• Li Q, Chang Y, Mu L, et al. MicroRNA-9 enhances chemotherapy sensitivity of glioma to TMZ by suppressing TOPO II via the NF-κB signaling pathway. Oncol Lett. 2019;17(6):4819–4826.
   PubMed Web of Science ®Google Scholar
• Fei X, Wang Z, Shi L, et al. PI3K inhibitor combined with miR-125b inhibitor sensitize TMZ-induced anti-glioma stem cancer effects through inactivation of Wnt/beta-catenin signaling pathway. Vitro Cellular Developmental Biol Anim. 2015;51(10):1047–1055.
   PubMed Web of Science ®Google Scholar
• Wu H, Liu Q, Cai T, et al. MiR-136 modulates glioma cell sensitivity to temozolomide by targeting astrocyte elevated gene-1. Diagn Pathol. 2014;9:173.
   PubMed Web of Science ®Google Scholar
• Zhou D, Lin X, Wang P, et al. Circular RNA circ_0001162 promotes cell proliferation and invasion of glioma via the miR-936/ERBB4 axis. Bioengineered. 2021;12(1):2106–2118.
   PubMed Web of Science ®Google Scholar
• Dallas S. Multidrug resistance-associated proteins: expression and function in the central nervous system. Pharmacol Rev. 2006;58(2):140–161.
   PubMed Web of Science ®Google Scholar
• Munoz M, Henderson M, Haber M, et al. Role of the MRP1/ABCC1 multidrug transporter protein in cancer. Iubmb Life. 2010;59:12.
   Google Scholar
• Schinkel AH. The roles of P-Glycoprotein and MRP1 in the blood-brain and blood-cerebrospinal fluid barriers. Adv Exp Med Biol. 2001;500:365–372.
   PubMed Web of Science ®Google Scholar
• Miranda A, Blanco-Prieto M, Sousa J, et al. Breaching barriers in glioblastoma. Part I: molecular pathways and novel treatment approaches. Int J Pharm. 2017;531(1):372–388.
   PubMed Web of Science ®Google Scholar
• Gao W, Jin Y, Hao J, et al. Hydroxyurea affects in vitro porcine oocyte maturation through increased apoptosis and oxidative stress. Biosci Rep. 2021. DOI:10.1042/bsr20203091
   Google Scholar
• Costa P, Gomes A, Braz M, et al. Escherichia coliApplication of the resazurin cell viability assay to monitor and typhimurium inactivation mediated by phages. Antibiotics (Basel, Switzerland). 2021;10(8). DOI: 10.3390/antibiotics10080974.
   Web of Science ®Google Scholar
• Guan B, Li G, Wan B, et al. RNA-binding protein RBM38 inhibits colorectal cancer progression by partly and competitively binding to PTEN 3ʹUTR with miR-92a-3p. Environ Toxicol. 2021. DOI:10.1002/tox.23356
   Web of Science ®Google Scholar
• Tang W, Zhang L, Li Z. Long noncoding RNA LOC100911498 is a novel regulator of neuropathic pain in rats. Brain Behav. 2021;e01966. DOI:10.1002/brb3.1966
   PubMed Web of Science ®Google Scholar
• Ma H, Jiang T, Tang W, et al. Transplantation of platelet-derived mitochondria alleviates cognitive impairment and mitochondrial dysfunction in db/db mice. Clin sci. 2020;134(16):2161–2175.
   Web of Science ®Google Scholar
• Munoz M, Henderson M, Haber M, et al. Role of the MRP1/ABCC1 multidrug transporter protein in cancer. IUBMB Life. 2007;59(12):752–757.
   PubMed Web of Science ®Google Scholar
• D’Angelo F, Ceccarelli M, Tala GL, et al. The molecular landscape of glioma in patients with neurofibromatosis 1. Nat Med. 2019;25(1):176–187.
   PubMed Web of Science ®Google Scholar
• Zhou L, Tang H, and Wang F, et al. Bioinformatics analyses of significant genes, related pathways and candidate prognostic biomarkers in glioblastoma. Mol Med Rep. 2018 Nov;182: 4185–4196.
   PubMedGoogle Scholar
• Yu Y, Villanueva-Meyer J, Grimmer M, et al. Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. Neuro Oncol. 2021. DOI:10.1093/neuonc/noab081
   Web of Science ®Google Scholar
• Tan J, Duan X, Zhang F, et al. Theranostic nanomedicine for synergistic chemodynamic therapy and chemotherapy of orthotopic glioma. Adv Sci (Weinheim, Baden-Wurttemberg, Germany). 2020;7(24):2003036.
   PubMedGoogle Scholar
• Mathur R, Zhang Y, Grimmer M, et al. MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence. Neuro Oncol. 2020;22(11):1580–1590.
   PubMed Web of Science ®Google Scholar
• Wang Q, Cai J, Fang C, et al. Mesenchymal glioblastoma constitutes a major ceRNA signature in the TGF-β pathway. Theranostics. 2018;8(17):4733–4749.
   PubMed Web of Science ®Google Scholar
• Miao Y, Zhao Y, Zhao L, et al. MiR-18a increased the permeability of BTB via RUNX1 mediated down-regulation of ZO-1, occludin and claudin-5. Cell Signal. 2015;27(1):156–167.
   PubMed Web of Science ®Google Scholar
• Lu C, Wei Y, Wang X, et al. DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma. Mol Cancer. 2020;19:1.
   PubMed Web of Science ®Google Scholar
• Carro MS, Lim WK, Alvarez MJ, et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature. 2010;463(7279):318–325.
   PubMed Web of Science ®Google Scholar
• Cao S, and Zheng L. MiR-378 has the capacity to serve as a diagnostic biomarker for prostate cancer patient. 2020. doi:10.21203/rs.3.rs-53222/v1.
   Google Scholar
• Liu K, Hu H, and Jiang H, et al. Transcription factor Runx1 activates opn to promote tumor progression in head and neck cancer. Carcinogenesis. 2021 Apr 17;42(3): 414–422.
   PubMedGoogle Scholar
• Turai P, Nyírő G, Butz H, et al. MicroRNAs, long non-coding RNAs, and circular RNAs: potential biomarkers and therapeutic targets in pheochromocytoma/paraganglioma. Cancers (Basel). 2021;13:7.
   Web of Science ®Google Scholar
• Lin Y, Chen T, Huang Y, et al. Involvement of microRNA in solid cancer: role and regulatory mechanisms. Biomedicines. 2021;9:4.
   Web of Science ®Google Scholar
• Zhang D, Ma S, Zhang C, et al. MicroRNA-935 directly targets FZD6 to inhibit the proliferation of human glioblastoma and correlate to glioma malignancy and prognosis. Front Oncol. 2021;11:566492.
   PubMed Web of Science ®Google Scholar
• Zhao L, Li R, Xu S, et al. Tumor suppressor miR-128-3p inhibits metastasis and epithelial-mesenchymal transition by targeting ZEB1 in esophageal squamous-cell cancer. Acta Biochim Biophys Sin (Shanghai). 2018. DOI:10.1093/abbs/gmx132
   Web of Science ®Google Scholar
• Shahzad U, Krumholtz S, Rutka J, et al. Noncoding RNAs in glioblastoma: emerging biological concepts and potential therapeutic implications. Cancers (Basel). 2021;13:7.
   Web of Science ®Google Scholar
• Liu T, Zhang X, Du L, et al. Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer. Mol Cancer. 2019;18:1.
   PubMed Web of Science ®Google Scholar
• Chen Y, Wu N, Liu L, et al. microRNA‐128‐3p overexpression inhibits breast cancer stem cell characteristics through suppression of Wnt signalling pathway by down‐regulating NEK2. J Cell Mol Med. 2020;24. DOI:10.1111/jcmm.15317.
   Web of Science ®Google Scholar
• Tong WY, Alnakhli M, Bhardwaj R, et al. Delivery of siRNA in vitro and in vivo using PEI-capped porous silicon nanoparticles to silence MRP1 and inhibit proliferation in glioblastoma. J Nanobiotechnology. 2018;16(1): 38-38.
   PubMedGoogle Scholar
• Huang M, Zhang D, Wu J, et al. Wnt-mediated endothelial transformation into mesenchymal stem cell-like cells induces chemoresistance in glioblastoma. Sci Transl Med. 2020;12:532.
   Web of Science ®Google Scholar
• Cole S. Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future. Annu Rev Pharmacol Toxicol. 2014;54:95–117.
   PubMed Web of Science ®Google Scholar
• Calatozzolo C, Pollo B, Botturi A, et al. Multidrug resistance proteins expression in glioma patients with epilepsy. J Neurooncol. 2012;110(1):129–135.
   PubMed Web of Science ®Google Scholar
• Amanda T, Zaitun Z, Caitr?-N O, et al. Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme. Front Neurosci. 2015;9:218.
   PubMed Web of Science ®Google Scholar
• Tivnan A, Zakaria Z, O’Leary C, et al. Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme. Front Neurosci. 2015;9:218.
   PubMed Web of Science ®Google Scholar
• Zhang T, Shao Y, Chu T, et al. MiR-135a and MRP1 play pivotal roles in the selective lethality of phenethyl isothiocyanate to malignant glioma cells. Am J Cancer Res. 2016;6(5):957–972.
   PubMed Web of Science ®Google Scholar
• Hasanzadeh Kafshgari M, Alnakhli M, Delalat B, et al. Small interfering RNA delivery by polyethylenimine-functionalised porous silicon nanoparticles. Biomater Sci. 2015;3(12):1555–1565.
   PubMed Web of Science ®Google Scholar